🔴 Quantum BioPharma is trading 5% down in after-hours trading with no fresh company-specific catalyst identified

Quantum BioPharma is trading 5.17% down now at $3.30 in after-hours trading, with no fresh August 12 company-specific announcement or earnings release identified to explain the decline.

• It fell from the August 12 regular-session close of $3.48.
• The latest major catalyst remains the FDA’s August 10 clearance allowing Lucid-MS to advance into Phase 2 development, which had supported earlier gains.
• Broader markets were modestly higher, so market direction does not clearly explain the drop; volume and activity-level data were unavailable.